ImmuCell to collaborate on bacteriocins

ImmuCell to collaborate on bacteriocins

IMMUCELL Corp. announced that it has entered into an exclusive option agreement to license new bacteriocin technology from the University of Massachusetts-Amherst.

This technology, developed by Dr. Margaret Riley and her colleagues in the department of biology, focuses on bacteriocins with activity against Gram-negative infections for use in combating mastitis in dairy cattle. This will broaden the company's pipeline of bacteriocin molecules to tre

All access premium subscription

This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.

Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)

Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit and click on Subscribe at the top of the page for more information.



Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.